These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 7969790

  • 1. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
    Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A.
    Neuroendocrinology; 1994 Sep; 60(3):314-22. PubMed ID: 7969790
    [Abstract] [Full Text] [Related]

  • 2. Absence of D2S dopamine receptor in the prolactin-secreting MMQ pituitary clone: characterization of a wild D2L receptor coupled to native transduction mechanisms.
    Ventra C, Meucci O, Grimaldi M, Scorziello A, Porcellini A, Schettini G.
    J Mol Endocrinol; 1995 Jun; 14(3):375-89. PubMed ID: 7669227
    [Abstract] [Full Text] [Related]

  • 3. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
    Li Q, Su Z, Liu J, Cai L, Lu J, Lin S, Xiong Z, Li W, Zheng W, Wu J, Zhuge Q, Wu Z.
    Mol Cell Endocrinol; 2014 Jan 25; 382(1):377-384. PubMed ID: 24184771
    [Abstract] [Full Text] [Related]

  • 4. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland.
    Oomizu S, Boyadjieva N, Sarkar DK.
    Alcohol Clin Exp Res; 2003 Jun 25; 27(6):975-80. PubMed ID: 12824819
    [Abstract] [Full Text] [Related]

  • 5. Resistance to bromocriptine in prolactinomas.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A.
    J Clin Endocrinol Metab; 1989 Sep 25; 69(3):500-9. PubMed ID: 2760167
    [Abstract] [Full Text] [Related]

  • 6. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
    Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A.
    J Neuroendocrinol; 1996 Oct 25; 8(10):737-46. PubMed ID: 8910802
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression.
    Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, Gunz G, Figarella-Branger D, Cortet-Rudelli C, Grisoli F, Jaquet P, Enjalbert A.
    J Clin Endocrinol Metab; 1996 Sep 25; 81(9):3390-6. PubMed ID: 8784102
    [Abstract] [Full Text] [Related]

  • 9. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.
    Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS, Wang CD, Lin C, Zeng YJ, Zhuge QC.
    J Neurooncol; 2010 Aug 25; 99(1):25-32. PubMed ID: 20063113
    [Abstract] [Full Text] [Related]

  • 10. Correlation of alternative splicing of the D2 dopamine receptor mRNA and estrogen receptor mRNA in the prolactinomas and gonadotrope tumors.
    Wu ZB, Li CZ, Zong XY, Su ZP, Zeng YJ, Zhang YZ.
    J Neurooncol; 2009 Aug 25; 94(1):135-9. PubMed ID: 19252821
    [Abstract] [Full Text] [Related]

  • 11. Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas.
    Su Z, Wang C, Wu J, Jiang X, Chen Y, Chen Y, Zheng W, Zhuge Q, Wu Z, Zeng Y.
    Neurol Sci; 2012 Apr 25; 33(2):275-9. PubMed ID: 21748460
    [Abstract] [Full Text] [Related]

  • 12. D2 dopaminergic receptors: normal and abnormal transduction mechanisms.
    Caccavelli L, Cussac D, Pellegrini I, Audinot V, Jaquet P, Enjalbert A.
    Horm Res; 1992 Apr 25; 38(1-2):78-83. PubMed ID: 1306522
    [Abstract] [Full Text] [Related]

  • 13. Antisense strategy unravels a dopamine receptor distinct from the D2 subtype, uncoupled with adenylyl cyclase, inhibiting prolactin release from rat pituitary cells.
    Valerio A, Alberici A, Tinti C, Spano P, Memo M.
    J Neurochem; 1994 Apr 25; 62(4):1260-6. PubMed ID: 8133260
    [Abstract] [Full Text] [Related]

  • 14. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine.
    Lei T, Bai X, Liu K, Hu W, Xue D, Jiang X.
    J Tongji Med Univ; 1998 Apr 25; 18(3):161-3. PubMed ID: 10806816
    [Abstract] [Full Text] [Related]

  • 15. Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression.
    Trouillas J, Chevallier P, Remy C, Rajas F, Cohen R, Calle A, Hooghe-Peters EL, Rousset B.
    Endocrinology; 1999 Jan 25; 140(1):13-21. PubMed ID: 9886801
    [Abstract] [Full Text] [Related]

  • 16. Estrogen inhibits D2S receptor-regulated Gi3 and Gs protein interactions to stimulate prolactin production and cell proliferation in lactotropic cells.
    Sengupta A, Sarkar DK.
    J Endocrinol; 2012 Jul 25; 214(1):67-78. PubMed ID: 22573829
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM, Perez-Millán MI, Ornstein AM, Cristina C, Becu-Villalobos D.
    J Pharmacol Exp Ther; 2011 Jun 25; 337(3):766-74. PubMed ID: 21406548
    [Abstract] [Full Text] [Related]

  • 18. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W, Riedl M, Luger A, Czech T, Rössler K, Asenbaum S, Angelberger P, Kornhuber J, Deecke L, Podreka I, Brücke T.
    J Nucl Med; 1996 Dec 25; 37(12):1931-7. PubMed ID: 8970508
    [Abstract] [Full Text] [Related]

  • 19. The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor.
    Xu R, Parlow AF, Wang Y.
    Brain Res; 2002 Jun 07; 939(1-2):95-9. PubMed ID: 12020855
    [Abstract] [Full Text] [Related]

  • 20. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
    Lloyd HM, Jacobi JM, Willgoss DA.
    Clin Endocrinol (Oxf); 1995 Jul 07; 43(1):79-85. PubMed ID: 7641414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.